The stock touched a high of Rs 135 and a low of Rs 118. It ended up 13% at Rs 133. A total of 307,678 stocks were traded on the BSE today.
Updated at 1105 hrs
Jubilant Organosys has zoomed 11% following news of its new drug, Sestamibi's gaining approval of the US Food and Drug Administration (FDA).
The stock opened flat at Rs 119. It soon surged to a high of Rs 132, up Rs 15 from yesterday's close. The stock is now trading at Rs 130 - up 11% (Rs 13). So far, 108,212 stocks have been traded on the BSE.
According to a release issued to the BSE yesterday, the company's subsidiary in the US, DRAXIMAGE: LLC has received the US FDA's approval for DRAXIMAGE's generic Sestamibi.
The drug is a bioequivalent and therapeutically equivalent to reference listed drug Cardiolite and will help to evaluate the flow of blood to the heart. The market size of the drug is being estimated at $400 million.
Further, the company today intimated the BSE that it has signed a research collaboration agreement with AstraZeneca.